PP405 is ineffective for miniaturized, fibrosed hairfollicles in androgenetic alopecia. AMP303 may activate hairfollicle stem cells, but minoxidil and finasteride are still the main treatments.
The conversation discusses the confusion over low testosterone potentially causing hair loss, with users sharing personal experiences and knowledge about hair loss treatments like Finasteride. Some users suggest that hairfollicle sensitivity to DHT, not testosterone levels, is the key factor in balding, and others discuss the side effects of hair loss medications.
The conversation covers aggressive hair regrowth treatments like Dutasteride, Minoxidil (oral and topical), RU58841, microneedling, and ketoconazole shampoo. It also mentions PRP, laser therapy, GHK-Cu injections, and hormone therapy for maximum regrowth.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
HairClone aims to rejuvenate miniaturizing hairfollicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hairfollicles, but full regenerative treatments will take many years to develop.